NCT04047160View on ClinicalTrials.gov

Safety, Tolerability of OP-724 in Patients With Primary Biliary Cholangitis (Phase I)

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

August 29, 2019

Primary Completion Date

September 21, 2021

Study Completion Date

March 31, 2022

Conditions
Primary Biliary Cholangitis (PBC)Liver Cirrhosis, Biliary
Interventions
DRUG

OP-724

Twice a week for 4 hours continuous intravenous administration of OP-724

Trial Locations (2)

113-8677

Tokyo Metropolitan Komagome Hospital, Bunkyō-Ku

812-8582

Kyushu University Hospital, Fukuoka

Sponsors
All Listed Sponsors
collaborator

Ohara Pharmaceutical Co., Ltd.

INDUSTRY

collaborator

Japan Agency for Medical Research and Development

OTHER_GOV

lead

Kiminori Kimura, MD

OTHER